Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Living Cell Technologies (LCT), a cell implant company, has reported that its subsidiary LCT Biomedical has received registration of the encapsulation device as a delivery system in Russia.
Subscribe to our email newsletter
LCT Biomedical was formed in 2009 to facilitate the commercial development of Diabecell in Russia. Diabecell is designed to normalise the lives of people with insulin dependent diabetes. Diabecell will be implanted into patients. It works by self-regulating insulin secretion in the patient’s body. LCT’s encapsulation technology means that this procedure does not require the use of immunosuppressant drugs.
LCT said that the registration allows for the production, sale and use of its capsules in all delivery applications – including cell, drug and biologics.
Paul Tan, CEO of LCT said: “The registration of LCT’s encapsulation technology is an important step in the commercial development of the company’s living cell products, particularly as the Russian standard is acceptable in Europe.
“In addition to LCT’s two lead products – Diabecell for treatment of Type 1 diabetes and NTCELL for the treatment of Parkinson’s disease – there is already interest in Russia for the use of the capsules as a drug and biologic delivery system.”
The company said that eight patients with insulin dependent diabetes have received between one and three implants of Diabecell with positive initial results in the clinical trial in Moscow.